| Sign In to gain access to subscriptions and/or personal tools. |
DOI: 10.1177/08830738030180021301 Epilepsy, Atherosclerosis, Myocardial Infarction, and CarbamazepineDepartment of Pathology and Laboratory Medicine, Drexel University College of Medicine and St. Chritopher's Hospital for Children, Philadelphia, Pennsylvania, JD37{at}drexel.edu
Department of Pediatrics, Section of Pediatric Neurology, Drexel University College of Medicine and St. Chritopher's Hospital for Children, Philadelphia, Pennsylvania
Department of Pediatrics, Section of Pediatric Neurology, Drexel University College of Medicine and St. Chritopher's Hospital for Children, Philadelphia, Pennsylvania
Department of Pathology and Laboratory Medicine Department of Pediatrics, Section of Pediatric Neurology Drexel University College of Medicine and St. Christopher's Hospital for Children, Philadelphia, Pennsylvania Epileptic patients receiving medications such as phenytoin or phenobarbital have been noted to have an exceedingly low incidence of myocardial infarction, but children treated with carbamazepine have shown alteration of their serum lipid profile that could predispose them to atherosclerosis. This report seems to corroborate this point and describes the findings in an 11-year-old boy who died following a major seizure, rhabdomyolysis, and renal failure. The autopsy demonstrated that he had marked coronary atherosclerosis and myocardial infarction. The child had been treated with carbamazepine for more than 10 years. (J Child Neurol 2003;18: 150151).
|